The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Monthly Archives: May 2011

Monday Biotech Deal Review: May 30, 2011

Welcome to your Monday Biotech Deal Review for Monday May 30, 2011.  This week features summaries of the previous two weeks’ events in the biotech space, following the May 24 holiday weekend.  There hasn’t been too much activity, however Valeant is on the move, acquiring AB Sanitas for EUR 314M in cash.  Read on to [...]

Biotech Trends Update — IP Constituencies: Innovator-Generic Mixing Continues in Canada

As traditional pharma companies continue to diversify their revenue sources in the face of their pending patent cliffs, we have followed their entry into and expansion of their generics business lines. We have also noted activity in the reverse – generics companies developing novel products to build their margins and take advantage of their production capacity and [...]

Friday Science Review: May 27, 2011

Functioning Neurons from Canine Embryonic Stem Cells University of Guelph ♦ University of Toronto ♦ Published in PLoS ONE, May 17, 2011 Scientists have successfully created functioning neural cells from canine embryonic stem cells (ESCs). The protocol used was similar to those used to create neural stem cells from human ESCs. In order to produce [...]

Friday Science Review: May 20, 2011

Genetic Architecture: How a Cell is Wired University of Toronto ♦ National Institute of Health ♦ Albert Einstein College of Medicine Published in Nature Biotechnology, May 15, 2011 A great deal of effort has been invested in elucidating the physical interactions of proteins in order to understand their functional relationships. The research community is also [...]

Valuation and other Biotech Mysteries Part 2: Some Basic Mathematics

[Please note that this blog series has not been pre-written. The subject of the next post in the series will be determined by where the current post leaves off and any questions that readers send me or leave as comments on the posts.] When you create a valuation spreadsheet, you are plugging in numbers representing [...]

Monday Biotech Deal Review: May 16, 2011

Welcome to your Monday Biotech Deal Review for May 16, 2011. Angiotech has completed its second amended and restated plan of compromise or arrangement, cleaning up USD$250M in debt in respect of 7.75% senior subordinated notes, which are now cancelled, and has also resulted in the restructuring of $325M of existing floating rate notes through [...]

Friday Science Review: May 13, 2011

Environmental Stimuli Enhance Visual System Function McGill University ♦ Published in Neuron (Cell Press), May 12, 2011 The developing nervous system utilizes sensory inputs to lay down the correct neural circuits, strengthening and weakening specific connections where necessary. Sensory cues from the external environment can play a role in neural development as well.  A new [...]

BIO World Congress on Industrial Biotechnology & Bioprocessing — Day 1 Review

We attended several sessions yesterday and learned about biofuels and bioproducts investment; bioingredients for food and nutrition; and strategies for profitable commercialization of renewable chemicals, among others. One of the highlights was the lunch plenary, where panelists Brian J.M. Ames (DOW Chemical),  Balu Sarma (Praj Matrix), Feike Sijbesma (DSM) and Peter Williams (INEOS Technologies) addressed a panel discussion entitled [...]

Valuation and Other Biotech Mysteries – Part 1

I have been doing valuations in various forms since 1981 when I started my MBA at York University. There are major differences between those initial valuations and the ones that I have been doing as a biotech stock analyst over much of the last 20 years. Those initial valuations were for assets or profitable companies, [...]

BIO World Congress on Industrial Biotechnology & Bioprocessing

This year’s World Congress on Industrial Biotechnology starts today in Toronto. A report from The Milken Institute released into the lead-up before the conference includes some interesting data: Industrial biotechnology received $1.48 billion in venture investment from 2004 to 2009, compared to $1.99 billion for biofuels and $17.48 billion for therapeutic biotech plays. Up to 78% of [...]

Monday Biotech Deal Review: May 9, 2011

Welcome to your Monday Biotech Deal Review for May 9, 2011.  Biotech activity was a bit slow last week.  Of note however is the minority shareholder oppression litigation launched against WEX Pharmaceuticals in the wake of the recent takeover by Pharmagesic (Holdings) Inc.  Read on to learn more.  

Friday Science Review: May 6, 2011

Heterochromatin Structures Disperse as Somatic Cells Move to Pluripotency University of Toronto ♦ Hospital for Sick Children ♦ Ontario Human iPS Cell Facility ♦ Sprott Centre for Stem Cell Research Published in EMBO Journal, May 4, 2011 Cellular reprogramming of adult cells is achieved through the introduction of genetic factors that make widespread changes to [...]

Monday Biotech Deal Review: May 2, 2011

Welcome to your Monday Biotech Deal Review for May 2, 2011.  This review is a double feature from last week’s Easter break.  Plenty happened in the interim, with Angiotech developments, private placements, licensing and other interesting corporate transactions and announcements.  Read on to learn more. 

Follow

Get every new post delivered to your Inbox.

Join 76 other followers